Pharming initiates equity fundraising

ID: 1015353
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

OR IN THE United States, Australia, Canada, Japan or South Africa.

Leiden, The Netherlands, May 27, 2010.  Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) announced on April 22, 2010 to investigate
the possibilities of attracting additional funding. Today, Pharming announces
that it has received a number of pre-commitments from existing and new
shareholders to participate in an intended equity offering of up to ?12 million,
by means of a private placement with institutional investors and qualifying
investors who subscribe for a minimum amount of ?50,000.

The net proceeds of such offering will be used for corporate activities, most
notably for the ongoing regulatory approval processes and start of
commercialization of Rhucin for the treatment of Hereditary Angioedema, and
selective development of subsequent indications of rhC1 inhibitor.

Pharming expects to be able to make further announcements on the intended
offering shortly.

About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. Pharming's lead product Rhucin® for acute attacks of
Hereditary Angioedema has passed clinical development stage and the Market
Authorization Application is under review with the European Medicines Agency.
Prodarsan® - a product under development by Pharming's subsidiary DNage - is in
early stage clinical development for Cockayne Syndrome and lactoferrin for use
in food products. The advanced technologies of the Company include innovative
platforms for the production of protein therapeutics, technology and processes
for the purification and formulation of these products, as well as technology in

the field of DNA repair (via DNage). Recently the partial spin- out of DNage was
initiated. Additional information is available on the Pharming

Not for distribution, directly or indirectly, in or into the United States,
Australia, Canada, Japan or South Africa or to US persons. This announcement is
not a prospectus and does not contain or constitute an offer for sale or the
solicitation of an offer to purchase securities in the United States, Australia,
Canada, Japan or South Africa or any other jurisdiction.

The securities mentioned herein have not been and will not be registered under
the US Securities Act of 1933, as amended (the "Securities Act"), and may not be
offered or sold in the United States absent registration under the Securities
Act or an available exemption from, or to or for the account of US persons (as
such term is defined in Regulation S under the Securities Act) or transaction
not subject to, the registration requirements of the Securities Act.

In the event that an offering will be pursued, a prospectus will be made
generally available in connection with the admission of the offered shares in
the capital of the Company to trading on Euronext Amsterdam by NYSE Euronext,
copies of which  will then be available at no cost through the website of
Euronext Amsterdam (Dutch residents only) and by sending a request in writing to
the Company.

This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.

Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6
109 299 54


Press release (PDF):

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 05/27/2010 - 02:00
Language: English
News-ID 1015353
Character count: 0
Firma: Pharming Group N.V.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Leiden


Number of hits: 142


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 76

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.